Literature DB >> 3007045

Advances in the biology of non-small cell lung cancer.

A F Gazdar.   

Abstract

We have initiated an in-depth, comprehensive study of non-SCLC in the expectation that improvements in clinical management and diagnosis of lung cancer patients will follow. We have established and characterized over 30 such tumors in long-term culture and as xenografts in athymic nude mice. These models usually retain the morphologic and other properties of the tumors from which they were derived. With the use of fully defined medium, most SCLC and adenocarcinomas can be established as long-term cultures. The growth conditions for squamous cell carcinomas have not been fully defined, and the success rate is low. In contrast to SCLC, there is considerable heterogeneity of non-SCLC tumors, with more than 12 phenotypes identified among the first 30 lines established. In addition, there is considerable overlap of properties, both within the non-SCLC types as well as between non-SCLC and SCLC. These findings indicate a common origin for all lung cancers. Radiation and drug sensitivity studies suggest that cell line data may correlate with clinical responses. Clinical protocols utilizing our ability to culture and drug test individual tumors are currently under way. They represent the first steps in a combined clinico-laboratory approach to the management of lung cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007045     DOI: 10.1378/chest.89.4.277s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Immunohistochemical demonstration of chromogranin A, chromogranin B, and secretoneurin in primary non-small-cell carcinomas of the lung.

Authors:  Martin Tötsch; Birgit Kunk; Barbara Dockhorn-Dworniczak; Dietmar Öfner; Reiner Fischer-Colbrie; Gregor Mikuz; Werner Böcker; Kurt Werner Schmid
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

2.  Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.

Authors:  S X Jiang; T Kameya; Y Sato; N Yanase; H Yoshimura; T Kodama
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.

Authors:  H H Heidtmann; U Salge; M Abrahamson; M Bencina; L Kastelic; N Kopitar-Jerala; V Turk; T T Lah
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lung carcinoma cell lines.

Authors:  C Liu; M S Tsao
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

5.  Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours.

Authors:  V Sundaresan; J G Reeve; S Stenning; S Stewart; N M Bleehen
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.